HCM

Hutchmed (China) Limited

14.30

+0.49+3.55%

Closed16:10 03/30 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE14.40/13.81

TODAY RANGE14.02-14.59

VOL176.52K

MARKET CAP2.49B

52 WEEK RANGE11.51-19.50

AVG VOL (3M)37.53K

% TURNOVER0.10%

TURNOVER0

P/E (TTM)5.46

% RANGE4.13%

EPS(TTM)2.617

P/E(FORWARD)160.46

P/B2.015

BVPS7.10

DIVIDEND--

P/S4.548

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP2.49B

SHARES OUTSTANDING174.47M

NEXT EARNINGS--

FREE FLOAT174.45M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·3h ago
Orient Securities Remains a Buy on HUTCHMED (China) (HCM)
TipRanks·3d ago
Hutchmed Expands Oncology Pipeline With New First‑in‑Human Solid Tumor Trial
TipRanks·03/24 07:05
HUTCHMED (China) (HCM) Gets a Buy from GF Securities
NASDAQ·03/23 08:28
HUTCHMED Initiates And Doses First Patient In Phase III Trial Of HMPL-760 For R/R DLBC Lymphoma
Reuters·03/23 00:01
HUTCHMED starts China Phase 3 trial of HMPL-760 plus R-GemOx in relapsed or refractory DLBCL
Reuters·03/23 00:00
HUTCHMED launches Phase III China trial of HMPL-760 plus R-GemOx in relapsed/refractory DLBCL
Reuters·03/18 21:53
HUTCHMED (China) Ltd. files initial beneficial ownership statement for Deputy CFO Lorenso Chiu
Reuters·03/16 11:46
HUTCHMED (China) Ltd. files Form 3 initial beneficial ownership statement for CEO and CSO Su Wei-guo
TipRanks·03/15 05:45
HUTCHMED (China) (HCM) Receives a Buy from SPDB
TipRanks·03/12 05:35
HUTCHMED (China) (HCM) Gets a Buy from CICC
Reuters·03/11 12:22
HUTCHMED (China) Ltd. Files Initial Beneficial Ownership Statement for Director and CFO Cheng Chig Fung
TipRanks·03/11 08:35
HUTCHMED (China) (HCM) Receives a Buy from BOCOM International Holdings Company
Dow Jones·03/10 18:07
HUTCHMED (China) Is Maintained at Buy by B of A Securities
Dow Jones·03/10 18:07
HUTCHMED (China) Price Target Cut to $20.00/Share From $21.00 by B of A Securities
TipRanks·03/10 11:30
Hutchmed price target lowered to $20 from $21 at BofA

Same Industry

Name/Symbol

Change%

Price

HCM

MCK

BIIB

AMGN

SHPG

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+0.40%

0.1005

Lilly Eli & Co

LLY

-2.09%

878.24

CELG

TXMD

Johnson & Johnson

JNJ

+0.51%

240.45

ABBV

Zoetis Inc

ZTS

+2.63%

116.33

Gilead Sciences Inc

GILD

-1.92%

134.25

NVO

BMY

ALXN

Pfizer

PFE

-1.92%

27.04

Sanofi FR

SNY

+0.34%

46.78

GCVRZ

Novartis

NVS

-1.02%

148.18

RDY

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.